GCTK Stock Jumps As Qare Data Platform Launch Fuels Momentum
GlucoTrack Inc. (GCTK) stock surged 14.04% on October 28, 2026, driven by the launch of its Qare data platform. The company's stock has seen significant volatility, trading at $1.95 after a 380% increase from its low. GlucoTrack reported a quarterly net loss of $3.8M and negative free cash flow. The Qare platform, focused on GLP-1 medications, aims to collect and compare patient data, potentially attracting partnerships. The company also expanded its ai² platform globally.
How this was made

The 30-second read
Why it matters
The Qare platform could create a data licensing revenue stream, but execution risk is high.
Market read
First report of a product launch that directly moved the stock, making the article a primary source for short‑term traders.
What to watch
Regulatory scrutiny of health data collection and the challenge of monetizing patient‑generated data are not addressed.
Background
GCTK is a low‑float micro‑cap that has been trading near $0.40 before a 380% rally to $1.95, driven by a new GLP‑1 data app launch.
Ticker impact
GCTK surged 14% intraday as the company launched its Qare GLP‑1 data platform, a fresh catalyst driving the price move.
likely short‑term upside as momentum traders chase the story, but pressure may build if the platform fails to gain users.
The article reports the first public disclosure of the Qare launch and its immediate market reaction, giving traders a concrete entry point.
Market effects
Highlights growing interest in GLP‑1 data assets, potentially spurring other micro‑caps to pursue similar health‑data platforms.
Limited to US micro‑cap space; no broader regional effect.
Shows how niche health‑tech narratives can drive short‑term price spikes in global biotech and AI‑related equities.
Counterpoint
The company’s deep cash deficits and lack of proven revenue streams could trigger a rapid sell‑off once the hype fades.
Key entities
- companyGlucoTrack Inc.
Issuer of GCTK, developer of Qare and ai² platform.
- subsidiaryLōkahi Therapeutics
Unit behind the Qare launch and ai² asset‑evaluation platform.
